Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028366 · ClinicalTrials.gov registry record · NA
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00028366 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants.
The verdict
NCT00028366, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study also will compare the effectiveness, safety, tolerability, and drug levels in the blood of these anti-HIV drug combinations.
Interventions
- DRUG Ritonavir
- DRUG Lopinavir/Ritonavir
- DRUG Tenofovir disoproxil fumarate
- DRUG Fosamprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Est. Completion | 2005-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028366
The ClinicalTrials.gov registry entry for NCT00028366 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00028366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028366 about?
NCT00028366 is a clinical study titled "Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People". Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study als...
What is the current status of trial NCT00028366?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00028366?
The interventions under investigation include: Ritonavir (DRUG), Lopinavir/Ritonavir (DRUG), Tenofovir disoproxil fumarate (DRUG), Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00028366?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.